跳至主要内容
临床试验/DRKS00023339
DRKS00023339进行中(未招募)不适用

Performance and Safety of thermotherapy with nanoparticles (NanoTherm® Therapy System) as an adjuvant therapy to the Standard of Care treatment of patients with recurrent glioblastoma - The NanoTherm Registry

MagForce AG0 个研究点目标入组 5 人开始时间: 2020年10月19日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Male and female patients with recurrent glioblastoma (first or repeated recurrence)
  • Age 18-75 Years
  • Informed Consent in writing
  • Karnofsky Index = 60
  • Life expectancy > 6 months
  • Failed standard therapy (Stupp regiment, TTF)
  • Stable corticoid requirements = 2mg dexamethasone / d
  • Known Molecular differentiation (MGMT promoter methylation, IDH mutation status, 1p/19q deletion status)
  • Cardiopulmonary compliance (heat and lying flat in the field generator for approx. 60 minutes must be tolerated
  • Psychological resilience

排除标准

  • Patients older than 75years
  • Pregnant or breast-feeding women
  • > 3 multiple glioblastoma lesions
  • Speech or motor brain functions in/at resection area
  • Subependymal contrast enhancement in adjacent ventricles
  • Simultaneous therapy with immunomodulators
  • Metallic implants =40cm from the planned alternating field, e.g. dental seals, cervical spine implants, implant remnants from previous craniotomies, orthopedic trauma osteosynthesis material, port systems with a metallic base
  • Electronic implants, e.g. cardiac pacemakers or defibrillators, cochlear implants, DBS
  • Allergy/hypersensitivity to aminosilanes, iron oxide, acetic acid
  • Planned or current therapy with Optune®TTF
  • Uncontrolled claustrophobia
  • Pain caused by arthrosis and degenerative spinal disorders, which may not be controlled

研究者

发起方
MagForce AG

相似试验